Jazz Pharmaceuticals PLC (JAZZ)

102.32
NASDAQ : Health Care
Prev Close 101.76
Day Low/High 101.80 / 103.40
52 Wk Low/High 95.80 / 160.00
Avg Volume 625.90K
Exchange NASDAQ
Shares Outstanding 59.89M
Market Cap 6.09B
EPS 5.40
P/E Ratio 17.79
Div & Yield N.A. (N.A)

Latest News

Jazz Pharmaceuticals Stock Retreats as Q3 Falls Short

Jazz Pharmaceuticals Stock Retreats as Q3 Falls Short

Jazz Pharmaceuticals's third-quarter results missed analysts' projections.

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

But we could see more volatility in the market.

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.

Jazz Pharmaceuticals (JAZZ) Stock Tumbles on Q2 Miss, Guidance

Jazz Pharmaceuticals (JAZZ) Stock Tumbles on Q2 Miss, Guidance

Jazz Pharmaceuticals (JAZZ) reported lower earnings and revenue for the 2016 second quarter and gave an outlook below Wall Street's expectations.

CMS Grants New Technology Add-On Payment To Defitelio For The Treatment Of Hepatic Veno-Occlusive Disease With Renal Or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation

CMS Grants New Technology Add-On Payment To Defitelio For The Treatment Of Hepatic Veno-Occlusive Disease With Renal Or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation

Add-On Payment to Provide Additional Medicare Reimbursement for Defitelio and to Support Patient Access in the Inpatient PPS Hospital Setting

3 Health Care Stocks Pushing The Sector Higher

3 Health Care Stocks Pushing The Sector Higher

TheStreet highlights 3 stocks pushing the health care sector higher today.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Jazz Pharma (JAZZ) Stock Receives ‘Outperform’ Rating at BMO Capital

Jazz Pharma (JAZZ) Stock Receives ‘Outperform’ Rating at BMO Capital

Jazz Pharma (JAZZ) stock coverage was started with an ‘outperform’ rating and $190 price target at BMO Capital.

Stocks Climb Slightly in May Despite Fed Fears

Stocks Climb Slightly in May Despite Fed Fears

U.S. markets ended May on a positive note, despite fears over the likelihood of a summer rate hike by the Federal Reserve that made trading unpredictable.

Stocks on Track for Mixed May as Dow Loses Gains

Stocks on Track for Mixed May as Dow Loses Gains

Stock are on track for a mixed month as escalating fears over the likelihood of a summer rate hike from the Federal Reserve erases gains for the Dow.

Stocks Waver as Boost in Spending Lifts Rate Hike Chances

Stocks Waver as Boost in Spending Lifts Rate Hike Chances

Stocks fluctuate Tuesday morning as a big boost in consumer spending in April increases the chances the Federal Reserve will implement another rate hike this summer.

Biotech M&A Waking Up After Long Nap

The uptick in the small- and mid-cap space bodes well for future capital appreciation.

Stock Futures Higher as Spending Sees Biggest Jump in Seven Years

Stock Futures Higher as Spending Sees Biggest Jump in Seven Years

Stock futures hold slight gains on Tuesday after consumer spending in April shows its best gain since August 2009.

Jazz Pharmaceuticals Strikes Celator Takeover Pact

Jazz Pharmaceuticals Strikes Celator Takeover Pact

The agreement will hand the Dublin company a promising pipeline drug to treat leukemia.

May 31 Premarket Briefing: 10 Things You Should Know

May 31 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are rising slightly Tuesday while European stocks fall as data indicate the eurozone remains in the grip of deflation.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Into Possible Securities Fraud Violations By Certain Officers And Directors Of Jazz Pharmaceuticals Plc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Into Possible Securities Fraud Violations By Certain Officers And Directors Of Jazz Pharmaceuticals Plc

Levi & Korsinsky announces it has commenced an investigation of Jazz Pharmaceuticals plc ("Jazz Pharmaceuticals" or the "Company") (NASDAQ:JAZZ) concerning possible violations of federal securities laws.